Called the SP-X Imaging and Analysis system, the benchtop platform combines Quanterix's high-sensitivity Simoa assays with higher levels of multiplexing.
Under the agreement, Expedeon will give Quanterix access to its CaptSure immunoassay products along with its Lightning-Link antibody labeling technology.
The company's shares grew 28 percent in September after it terminated a licensing deal with BioMérieux and regained control of certain intellectual property.
The effort will use Quanterix's Simoa technology and will focus initially on development of an assay for measuring the liver toxicity biomarker microRNA-122.
Near-term the deal gives Quanterix a CLIA lab while securing technologies that could improve assay multiplexing and support its longer term clinical goals.
The company said its recent $74 million IPO was done largely to drive awareness among biotech and pharma firms of its ultrasensitive immunoassay technology.
Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.
Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.
